Acquired ichthyosis (AI) is a reactive cutaneous manifestation that can be associated with malignant hematological disease, including cutaneous T-cell lymphoma (CTCL). Since it is difficult to distinguish AI from ichthyosiform mycosis fungoides, to select the treatment for CTCL with ichthyosis-like appearance and to evaluate its efficacy is sometimes challenging. In this report, we describe a case of primary cutaneous peripheral T-cell lymphoma not otherwise specified presenting AI successfully treated with oral bexarotene. In the present case, the administration of oral bexarotene was not only effective for lymphoma cells infiltrating ulcers and nodules, but it also eliminated AI.
Introduction
Acquired ichthyosis (AI) is a reactive cutaneous manifestation that can be associated with malignant hematological disease, including cutaneous T-cell lymphoma (CTCL) [1] . Among the various lymphomas, CD30+ lymphomas, such as Hodgkin lymphomas and CD30+ lymphoproliferative disorders (anaplastic large-cell lymphoma, lymphomatoid papulosis), occasionally present an ichthyosiform appearance and merely cause other variants of CTCL, including peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). On the other hand, ichthyosiform mycosis fungoides (MF) is a rare variant of MF, histologically showing epidermotropic infiltration of atypical lymphocytes [2] [3] [4] . In this report, we describe a case of primary cutaneous PTCL-NOS presenting AI successfully treated with oral bexarotene.
Case Report
A 45-year-old Japanese man visited our outpatient clinic with a 5-year history of systemic ichthyosis-like scaly erythema with subcutaneous nodules on the wrist and lower leg. On his initial visit, physical examination revealed prominent, large scales on the extensor surface of the extremities (Fig. 1a ). Moreover, elastic, subcutaneous nodules were detected on the bilateral wrists ( Fig. 1b) . A biopsy specimen from the left wrist revealed atypical lymphoid cells densely infiltrated from the upper dermis to the subcutaneous tissue ( Fig. 1c ). In contrast, few atypical, large cells were detected in the lesional skin of an ichthyosis-like eruption ( Fig. 1d ). Immunohistochemical staining revealed that these atypical lymphocytes, which were distributed throughout the dermis, were positive for CD3, CD4, CD5, and CD45, and negative for CD7, CD8, and CD30. Assessment of T-cell receptor (TCR) gene rearrangement by Southern blot analysis confirmed the monoclonality of the TCRβ chain. A full blood count and biochemical profile revealed slightly increased levels of serum IL-2R (634 U/mL) and normal levels of serum LDH (195 U/L). We screened for possible metastatic lesions with positron emission tomography and found no evidence of lymph node swelling or visceral lesions. From the above findings, we diagnosed the patient as having primary cutaneous PTCL-NOS (T3N0M0 stage IIB) presenting AI. We first treated the patient with oral prednisolone 30 mg/day without any effects. During oral intake of prednisolone, he developed an ulcer with prominent necrotic tissue on the right shin ( Fig. 2a ), and we administered etoposide 50 mg/day for 1 year. The necrotic ulcer gradually improved with scarring, but a deep, vermicular ulcer remained (Fig. 2b) . Moreover, around the ulcer, a prominent adherence of large scales still remained. We then administered oral bexarotene 300 mg/m 2 /day. The ulcer was cured with scarring, and the ichthyosis-like scales diminished within 8 weeks after the administration of bexarotene (Fig. 2c) . The elastic subcutaneous nodules on the bilateral wrists also regressed during the 8 weeks.
Discussion
AI is a reactive cutaneous manifestation that may be associated with malignant hematological disease, including CTCL [5] . On the other hand, ichthyosiform MF is a rare variant of MF, histologically showing epidermotropic infiltration of atypical lymphocytes [2] [3] [4] . Since an ichthyosiform eruption contains sparsely infiltrating lymphocytes, it is difficult to distinguish AI and ichthyosiform MF by clinical appearance, immunohistochemical staining, or analysis of the TCR rearrangement. Therefore, to select a treatment for CTCL with an ichthyosis-like appearance and to evaluate its efficacy is sometimes challenging. In this report, we describe a case of primary cutaneous PTCL-NOS presenting AI successfully treated with oral bexarotene. In the present case, the administration of oral bexarotene was effective not only for the lymphoma-infiltrating ulcers and nodules, but it also eliminated the AI.
Bexarotene is a third-generation retinoid X receptor-selective retinoid, which is administered for the treatment for CTCLs. The mechanisms of its antitumor effects are diverse [6] . For example, bexarotene produces dose-dependent apoptosis of CTCL cells by reducing the serum IL-4 in patients with Sézary syndrome [7] . In another report, bexarotene reduced the expression of CCR4 and E-selectin, leading to suppressed migration of CTCL cells in the lesional skin [8] . Notably, the production of CCL17 and CCL22 from tumor-associated macrophages (TAMs) is augmented by the stimulation of IL-4 [5, 9] , which is abundant in the cancer stroma of advanced MF [10] . Since TAMs are necessary for the formation of CTCLs in the lesional skin [11] , the decreased levels of IL-4 by the administration of bexarotene could reduce both chemokines from TAMs and the expression of chemokine receptors on CTCL cells, leading to the suppression of cancer formation in the lesional skin of CTCL.
In addition to the immunomodulation, bexarotene effects the proliferation and differentiation of epidermal keratinocytes [12, 13] . Indeed, these previous reports suggested that retinoid X receptor activation by bexarotene induces normalization of keratinocyte differentiation, leading to its therapeutic effects on psoriasis [12, 13] . Although the suppression of CTCL itself might effect the AI as a dermadrome of lymphomas, the effects of bexarotene on keratinocytes might have improved the AI appearance in our present case. This report presents only a single case, but further cases may provide fundamental insights into the mechanisms of the effects of bexarotene on lymphomas and AI.
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